Email:
global@GCP-ClinPlus.com
The National Clinical Research Center for Respiratory Diseases has conferred upon GCP ClinPlus the "National Excellence Award for Influenza Clinical Research Collaboration," honoring the company's professional excellence and innovative spirit in two landmark studies:
Phase II randomized, double-blind, placebo-controlled trial of ZSP1273 tablets in adults with acute uncomplicated influenza A
Phase III randomized, double-blind, placebo- or oseltamivir-controlled trial of ZSP1273 tablets in the same indication
The award was adjudicated by an expert panel led by Academician Zhong Nanshan, founding director of the National Respiratory Medicine Center, and represents the highest accolade in China's respiratory-disease clinical-research community.
Established in August 2013 and anchored at the First Affiliated Hospital of Guangzhou Medical University, the National Clinical Research Center for Respiratory Diseases coordinates a nationwide innovation network spanning 29 provinces and >250 prefecture-level cities. The center—dual-certified as a State Key Laboratory and a National Clinical Research Center—has played pivotal roles in combating SARS, avian influenza, and COVID-19.
During the review, GCP ClinPlus was lauded for its standardized operating procedures, high-quality data outputs, and breakthrough findings. The award affirms not only technical prowess but also the company's sense of public-health responsibility.
For more than two decades, GCP ClinPlus has completed >2,200 clinical trials and helped bring >210 innovative products to market across respiratory diseases, CGT, oncology, endocrinology, and metabolism.
Within respiratory medicine, the company has deep experience in COPD, respiratory-tract infections, pneumonia (including TB), asthma, chronic pharyngitis, and rhinitis. Leveraging advanced biostatistics, forward-looking medical strategy, and full-service trial management, GCP ClinPlus partners with premier hospitals worldwide to deliver efficient, high-quality studies. This award underscores the industry’s recognition of its outstanding contribution to multicenter influenza research.
"Receiving this award is both an honor and a responsibility," said Executive President Hao Yonghong. "We will remain client-centric and science-driven, deepening collaboration with innovators worldwide to accelerate breakthrough therapies."
Rooted in the vision "to be the world's most trusted clinical-research solutions provider," GCP ClinPlus uses data science to elevate study quality. To date, the company has supported the launch of >210 products, including several respiratory blockbusters.
The National Excellence Award for Influenza Clinical Research Collaboration celebrates GCP ClinPlus's data-centric philosophy and clinical excellence. Moving forward, the company will continue to power China's clinical research to new heights and contribute Chinese wisdom to global public health.
NEXT